NICE Technology Appraisals (15th December 2008)
The National Institute for Health and Clinical Excellence (NICE) is acknowledged as a world leader in its field, yet the prevailing media image of NICE is as a controversial mechanism for denying patients expensive new drugs. Teresa Poole looks at how NICE appraises new and existing drugs through clinical and economic evidence and looks at the impact of those appraisals, including difficulties with implementation of the recommendations. The briefing, published by King’s Fund, assesses recent policy proposals to address the system's perceived shortcomings, including speeding up appraisals, setting a suitable threshold for cost-effectiveness and overcoming the problem of 'postcode prescribing', where there are significant geographical disparities in the availability of individual drugs not covered by NICE guidance.
Briefing
Latest Implementation Tools (10th December 2008)
These are the latest implementation tools to help with previously published NICE Guidance.
Lung cancer (non-small-cell) - erlotinib Costing Statement and Audit Support
Metastatic spinal cord compression Costing Report, Costing Template and Slide Set
Transabdominal artificial bowel sphincter implantation for faecal incontinence Audit Support
Attention deficit hyperactivity disorder (ADHD) Implementation Advice
Febuxostat for the management of hyperuricaemia in people with gout Technology Appraisal TA164 (17th December 2008)
Febuxostat is recommended as a possible treatment for chronic hyperuricaemia in people with gout only if: they can't take the medicine allopurinol for medical reasons or the side effects of allopurinol are so bad that the person either has to stop taking it or can't be given the most effective dose. People who were already taking febuxostat when the guidance was issued should be able to carry on taking it until they and their healthcare professional(s) decide that it is the right time to stop treatment.
Guidance
Infliximab for the treatment of acute exacerbations of ulcerative colitis Technology Appraisal TA163 (17th December 2008)
Infliximab is recommended as a possible treatment for people with acute, severely active ulcerative colitis only if: ciclosporin is considered inappropriate for them, or they are taking part in a research study (clinical trial)
Guidance
When to suspect child maltreatment: guideline consultation (16th December 2008)
A clinical practice guideline on “ When to suspect child maltreatment” is being developed for use in the NHS in England, Wales and Northern Ireland. Registered stakeholders for this guideline are invited to comment on the provisional recommendations. Closing date for comments is 10th February 2009.
Consultation
The National Institute for Health and Clinical Excellence (NICE) is acknowledged as a world leader in its field, yet the prevailing media image of NICE is as a controversial mechanism for denying patients expensive new drugs. Teresa Poole looks at how NICE appraises new and existing drugs through clinical and economic evidence and looks at the impact of those appraisals, including difficulties with implementation of the recommendations. The briefing, published by King’s Fund, assesses recent policy proposals to address the system's perceived shortcomings, including speeding up appraisals, setting a suitable threshold for cost-effectiveness and overcoming the problem of 'postcode prescribing', where there are significant geographical disparities in the availability of individual drugs not covered by NICE guidance.
Briefing
Latest Implementation Tools (10th December 2008)
These are the latest implementation tools to help with previously published NICE Guidance.
Lung cancer (non-small-cell) - erlotinib Costing Statement and Audit Support
Metastatic spinal cord compression Costing Report, Costing Template and Slide Set
Transabdominal artificial bowel sphincter implantation for faecal incontinence Audit Support
Attention deficit hyperactivity disorder (ADHD) Implementation Advice
Febuxostat for the management of hyperuricaemia in people with gout Technology Appraisal TA164 (17th December 2008)
Febuxostat is recommended as a possible treatment for chronic hyperuricaemia in people with gout only if: they can't take the medicine allopurinol for medical reasons or the side effects of allopurinol are so bad that the person either has to stop taking it or can't be given the most effective dose. People who were already taking febuxostat when the guidance was issued should be able to carry on taking it until they and their healthcare professional(s) decide that it is the right time to stop treatment.
Guidance
Infliximab for the treatment of acute exacerbations of ulcerative colitis Technology Appraisal TA163 (17th December 2008)
Infliximab is recommended as a possible treatment for people with acute, severely active ulcerative colitis only if: ciclosporin is considered inappropriate for them, or they are taking part in a research study (clinical trial)
Guidance
When to suspect child maltreatment: guideline consultation (16th December 2008)
A clinical practice guideline on “ When to suspect child maltreatment” is being developed for use in the NHS in England, Wales and Northern Ireland. Registered stakeholders for this guideline are invited to comment on the provisional recommendations. Closing date for comments is 10th February 2009.
Consultation
No comments:
Post a Comment